126 related articles for article (PubMed ID: 38470545)
21. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C; Osdoit M; van der Noordaa M; Shad S; Wei J; de Croze D; Hamy AS; Laé M; Reyal F; Sonke GS; Steenbruggen TG; van Seijen M; Wesseling J; Martín M; Del Monte-Millán M; López-Tarruella S; ; Boughey JC; Goetz MP; Hoskin T; Gould R; Valero V; Edge SB; Abraham JE; Bartlett JMS; Caldas C; Dunn J; Earl H; Hayward L; Hiller L; Provenzano E; Sammut SJ; Thomas JS; Cameron D; Graham A; Hall P; Mackintosh L; Fan F; Godwin AK; Schwensen K; Sharma P; DeMichele AM; Cole K; Pusztai L; Kim MO; van 't Veer LJ; Esserman LJ; Symmans WF
Lancet Oncol; 2022 Jan; 23(1):149-160. PubMed ID: 34902335
[TBL] [Abstract][Full Text] [Related]
22. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
26. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
28. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
30. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
[TBL] [Abstract][Full Text] [Related]
31. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
33. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
34. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
35. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
[TBL] [Abstract][Full Text] [Related]
36. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
[TBL] [Abstract][Full Text] [Related]
37. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
38. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
[TBL] [Abstract][Full Text] [Related]
39. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
40. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
